This 2019 review by Morgentaler and Caliber examines the evolving perspective on testosterone therapy (TTh) in men with prostate cancer (PCa). Historically contraindicated, TTh is now considered a viable option for certain patients. The review discusses the "saturation model," which suggests that prostate tissue's response to androgens plateaus beyond a
